Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) (KMM-97)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by Chonnam National University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Chonnam National University Hospital
ClinicalTrials.gov Identifier:
NCT01114048
First received: April 28, 2010
Last updated: September 21, 2011
Last verified: September 2011

April 28, 2010
September 21, 2011
March 2010
March 2012   (final data collection date for primary outcome measure)
response rate for induction chemotherapy [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01114048 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) Who Are Eligible for Autologous Stem Cell Transplantation: Multicenter Phase 2 Study

In this study, the investigators will analyze the long-term outcomes of remission and survival, and identify those with primary resistant disease as more likely to benefit from CTD (thalidomide, cyclophosphamide, dexamethasone) and early intensification of Vel-CD (bortezomib and CD) as induction chemotherapy followed by autologous stem cell transplantation for the patients with newly diagnosed multiple myeloma.

This study aims to assess the efficacy and toxicities of CTD and Vel-CD induction followed by high-dose therapy with autologous stem cell transplantation as a first line treatment for the patients with multiple myeloma.The investigators already investigated the thalidomide-based chemotherapy in patients with newly diagnosed MM. The combined regimen consisted of cyclophosphamide, thalidomide and dexamethasone (CTD) for induction treatment. CTD chemotherapy resulted in a favorable response with 79.4% overall response rate including 42.6% complete response (CR) or very good partial complete response (VGPR), and tolerable toxicity in MM patients. Moreover, CTD chemotherapy did not affect the yield of the stem cell collection.The investigators also published that the clinical efficacy and safety of a four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was assessed for patients with relapsed or refractory multiple myeloma Vel-CTD chemotherapy.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
Drug: Thalidomide, cyclophosphamide, dexamethasone, bortezomib
  1. Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1~28 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D 1~4, 15-18 Repeated every 28 days
  2. Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days

    • Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
78
Not Provided
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Newly diagnosed MM
  2. Aged between 18 and 65 years old
  3. With following measurable lesions (serum M-protein ≥ 1 g/dL or urine M-protein ≥ 400 mg/day, or free light chain ≥ 100 mg/L)

Exclusion Criteria:

  1. Smoldering or indolent myeloma
  2. ECOG performance status > 3 point
  3. Known hypersensitivity to cyclophosphamide, thalidomide or dexamethasone
  4. Peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by NCI CTCAE version 3
  5. Uncontrolled or severe cardiovascular disease, including MI within 6 months of enrolment, NYHA Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis, cardiac ejection fraction <0.5 : Severe conduction disorder : Hypotension (sitting systolic BP ≤ 100 mmHg and/or sitting diastolic BP ≤ 60 mmHg
  6. Impaired hepatic function (AST or ALT ≥ x 3 upper normal, T-bilirubin ≥ x 2 upper normal)
  7. Creatinine clearance < 20 ml/min
  8. Corrected serum calcium ≥ 14 mg/dL
  9. Sepsis or current active infection
  10. Pregnancy or breast feeding
  11. Uncontrolled Diabetes Mellitus
  12. Previous history of Recurrent DVT or pulmonary embolism
  13. Active ulcers detected by gastroscopy
  14. Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  15. Receipt of extensive radiation therapy within 4 weeks
Both
18 Years to 65 Years
No
Contact: Je-Jung Lee, M.D. and Ph.D. 82-61-3797638 drjejung@chonnam.ac.kr
Contact: Deok-Hwan Yang, M.D. and Ph.D. 82-61-3797636 drydh1685@gmail.com
Korea, Republic of
 
NCT01114048
KMM-97
Yes
Je-Jung Lee, associate professor, Chonnam National University Hwasun Hospital
Chonnam National University Hospital
Not Provided
Not Provided
Chonnam National University Hospital
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP